Claritas Pharmaceuticals, Inc. CLAZF
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -37.47% | 49.18% | -55.59% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -37.47% | 49.18% | -71.35% | ||
| Operating Income | 37.47% | -49.18% | 71.35% | ||
| Income Before Tax | 212.07% | -64.80% | -119.93% | ||
| Income Tax Expenses | -- | -- | -4,227.27% | ||
| Earnings from Continuing Operations | 212.07% | -64.80% | -116.50% | ||
| Earnings from Discontinued Operations | -- | 91.39% | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 143.83% | 77.57% | -116.50% | ||
| EBIT | 37.47% | -49.18% | 71.35% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 133.55% | 82.36% | -115.63% | ||
| Normalized Basic EPS | 146.15% | -29.67% | -110.33% | ||
| EPS Diluted | 133.55% | 82.36% | -115.63% | ||
| Normalized Diluted EPS | 146.15% | -29.67% | -110.33% | ||
| Average Basic Shares Outstanding | 30.75% | 27.15% | 5.60% | ||
| Average Diluted Shares Outstanding | 30.75% | 27.15% | 5.60% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||